Revelation Biosciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 10.83 million compared to USD 11.99 million a year ago. Basic loss per share from continuing operations was USD 602.7001.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.154 USD | -1.19% | +5.08% | -85.66% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-85.66% | 3.56M | |
+2.61% | 42.75B | |
+47.70% | 41.61B | |
+12.00% | 41.34B | |
-8.83% | 26.59B | |
+7.92% | 25.49B | |
-22.62% | 18.12B | |
+30.71% | 12.24B | |
-1.48% | 11.76B | |
+8.70% | 11B |
- Stock Market
- Equities
- REVB Stock
- News Revelation Biosciences, Inc.
- Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022